General Information of Drug (ID: DMHOF7T)

Drug Name
MEHD-7945A Drug Info
Synonyms RG-7597; EGFR/HER3 dual monoclonal antibody, Genentech
Indication
Disease Entry ICD 11 Status REF
Colorectal cancer 2B91.Z Phase 2 [1]
Solid tumour/cancer 2A00-2F9Z Phase 2 [2]
Cross-matching ID
TTD Drug ID
DMHOF7T

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [5]
Lapatinib DM3BH1Y Breast cancer 2C60-2C65 Approved [6]
Gefitinib DM15F0X Colon adenocarcinoma Approved [7]
Erlotinib DMCMBHA Adrenal gland neoplasm Approved [8]
Vandetanib DMRICNP Solid tumour/cancer 2A00-2F9Z Approved [9]
Dacomitinib DMOH8VY Non-small-cell lung cancer 2C25.Y Approved [10]
BIBW 2992 DMTKD7Q Non-small-cell lung cancer 2C25.Y Approved [11]
SKI-758 DMQ8E9R Ischemia 8B10-8B11 Approved [12]
Epidermal growth factor DMVONE6 Vulnerary ND56.Z Approved [10]
Merimepodib DM0HS92 Breast cancer 2C60-2C65 Approved [13]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
MM-141 DM2RJ4D Pancreatic cancer 2C10 Phase 2 [14]
Seribantumab DMYT470 Colorectal cancer 2B91.Z Phase 2 [15]
CDX-3379 DM5GKYD Squamous cell carcinoma 2B60-2D01 Phase 2 [15]
MM-121 DMDJRU1 Breast cancer 2C60-2C65 Phase 2 [16]
Elisidepsin DMB38KH Psoriasis vulgaris EA90 Phase 2 [17]
Zenocutuzumab DM1FLHH Pancreatic cancer 2C10 Phase 2 [18]
Sym013 DMZM6I2 Epithelial ovarian cancer 2B5D Phase 1/2 [19]
Zenocutuzomab DMMQGPE Solid tumour/cancer 2A00-2F9Z Phase 1/2 [20]
LJM716 DMGTB5N Breast cancer 2C60-2C65 Phase 1/2 [21]
AMG888/U3-1287 DMEF4L5 Non-small-cell lung cancer 2C25.Y Phase 1/2 [22]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Epidermal growth factor receptor (EGFR) TTGKNB4 EGFR_HUMAN Modulator [3]
Erbb3 tyrosine kinase receptor (Erbb-3) TTDC8N2 ERBB3_HUMAN Modulator [4]

References

1 ClinicalTrials.gov (NCT01577173) A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck
2 ClinicalTrials.gov (NCT01652482) A Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wild-Type Metastatic Colorectal Cancer. U.S. National Institutes of Health.
3 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
4 Company report (Biooncology)
5 Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.
6 Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
7 Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72.
8 Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48.
9 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
10 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
11 Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
12 Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
13 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
14 MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Mol Cancer Ther. 2014 Feb;13(2):410-25.
15 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
16 Company report (Merrimack)
17 Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models. Eur J Cancer. 2009 Jul;45(10):1855-64.
18 Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements. Cancer Discov. 2022 May 2;12(5):1233-1247.
19 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
20 Clinical pipeline report, company report or official report of Merus.
21 An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin. Cancer Res. 2013 Oct 1;73(19):6024-35.
22 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1798).